BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Trintellix (Vortioxetine) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Trintellix (Vortioxetine)\, from Clinical
 Trials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06805266-845@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Trintellix (Vortioxetine): Phase 4 readout est. (NCT06805266)
DESCRIPTION:Trintellix (Vortioxetine)\, phase 4.\nStudy: Vortioxetine for D
 epressive Symptoms and Freezing of Gait in Parkinson Disease\nEstimated pr
 imary completion: December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/vortioxetine#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06805266
URL:https://assetmemo.bio/drug/vortioxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05814640-845@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Trintellix (Vortioxetine): Phase 1/2 readout est. (NCT05814640)
DESCRIPTION:Trintellix (Vortioxetine)\, phase 1/2.\nStudy: Sequenced Treatm
 ent Alternatives to Relieve Adolescent Depression (STAR-AD)\nEstimated pri
 mary completion: 31 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/vortioxetine#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05814640
URL:https://assetmemo.bio/drug/vortioxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07266545-845@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trintellix (Vortioxetine): Phase 4 readout est. (NCT07266545)
DESCRIPTION:Trintellix (Vortioxetine)\, phase 4.\nStudy: RNA Editing as a B
 iomarker of Antidepressant Response in Unipolar and Bipolar Depression (ED
 IT-ANDRE)\nEstimated primary completion: 31 December 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/vortioxetine#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07266545
URL:https://assetmemo.bio/drug/vortioxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06604520-845@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Trintellix (Vortioxetine): Phase 2 readout est. (NCT06604520)
DESCRIPTION:Trintellix (Vortioxetine)\, phase 2.\nStudy: Vortioxetine for t
 he Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia\nEs
 timated primary completion: 31 May 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/vortioxetine#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06604520
URL:https://assetmemo.bio/drug/vortioxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284628-845@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Trintellix (Vortioxetine): Phase 2 readout est. (NCT07284628)
DESCRIPTION:Trintellix (Vortioxetine)\, phase 2.\nStudy: Vortioxetine for N
 ewly Diagnosed Glioblastoma\nEstimated primary completion: June 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/vortioxetine#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07284628
URL:https://assetmemo.bio/drug/vortioxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07204314-845@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Trintellix (Vortioxetine): Phase 3 readout est. (NCT07204314)
DESCRIPTION:Trintellix (Vortioxetine)\, phase 3\, Major Depressive Disorder
 .\nStudy: A Study of Vortioxetine in Japanese Pediatric Patients With Majo
 r Depressive Disorder\nEstimated primary completion: 30 September 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/vortioxetine#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07204314
URL:https://assetmemo.bio/drug/vortioxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
